<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="letter"><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with OASIS Tables v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archive-oasis-article1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jpoasis-nisons2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">Am J Physiol Heart Circ Physiol</journal-id><journal-id journal-id-type="iso-abbrev">Am. J. Physiol. Heart Circ. Physiol</journal-id><journal-id journal-id-type="pmc">ajpheart</journal-id><journal-id journal-id-type="publisher-id">Am J Physiol Heart Circ Physiol</journal-id><journal-id journal-id-type="publisher-id">AJPHEART</journal-id><journal-title-group><journal-title>American Journal of Physiology - Heart and Circulatory Physiology</journal-title></journal-title-group><issn pub-type="ppub">0363-6135</issn><issn pub-type="epub">1522-1539</issn><publisher><publisher-name>American Physiological Society</publisher-name><publisher-loc>Bethesda, MD</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7191629</article-id><article-id pub-id-type="publisher-id">H-00215-2020</article-id><article-id pub-id-type="publisher-manuscript">H-00215-2020</article-id><article-id pub-id-type="doi">10.1152/ajpheart.00215.2020</article-id><article-categories><subj-group subj-group-type="heading"><subject>Letter to the Editor</subject></subj-group></article-categories><title-group><article-title>Letter to the Editor: Angiotensin-converting enzyme 2: an ally or a Trojan horse? Implications to SARS-CoV-2-related cardiovascular complications</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Abassi</surname><given-names>Zaid</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Assady</surname><given-names>Suheir</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref></contrib><contrib contrib-type="author"><name><surname>Khoury</surname><given-names>Emad E.</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Heyman</surname><given-names>Samuel N.</given-names></name><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><aff id="aff1"><sup>1</sup>Department of Physiology and Biophysics, Rappaport Faculty of Medicine, <institution>Technion-Israel Institute of Technology</institution>, <addr-line>Haifa</addr-line>, <country>Israel</country></aff><aff id="aff2"><sup>2</sup>Laboratory Medicine, Rambam Health Care Campus, <addr-line>Haifa</addr-line>, <country>Israel</country></aff><aff id="aff3"><sup>3</sup>Department of Nephrology and Hypertension, Rambam Health Care Campus, <addr-line>Haifa</addr-line>, <country>Israel</country></aff><aff id="aff4"><sup>4</sup>Department of Medicine, Hadassah Hebrew University Hospital, Mount Scopus, Jerusalem, Israel</aff></contrib-group><author-notes><corresp id="cor1">Address for correspondence: Z. Abassi, Dept. of Physiology &#x00026; Biophysics, Rappaport Faculty of Medicine, Technion-IIT, PO Box 9649, Haifa, 31096, Israel (e-mail: <email>abassi@tx.technion.ac.il</email>).</corresp><fn id="afn1"><p>Editor&#x02019;s Note: This Letter to the Editor is a response to the current concern in understanding the mechanisms of infection by COVID-19, the virus that is currently circling the globe and potentially may be responsible for high levels of mortality and morbidity in the vulnerable population. Patients with cardiopulmonary disorders are especially at risk. In our desire to develop new and perhaps unconventional therapies, the cellular and molecular mechanisms responsible for membrane binding and internalization of the virus are especially important. The <italic>American Journal of Physiology-Heart and Circulatory Physiology</italic> is committed to providing a forum for discussion of these potential therapies and rigorous original research that can guide therapy in an evidence-based manner. We encourage our readers to submit any relevant research articles or commentary (as a Letter to the Editor) concerning COVID&#x02010;19, SARS&#x02010;Cov&#x02010;2, and cardiovascular disease. Editor-in-Chief Irving H. Zucker, PhD.</p></fn></author-notes><pub-date pub-type="ppub"><day>1</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="pmc-release"><day>1</day><month>5</month><year>2020</year></pub-date><!-- PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="ppub"/>. --><volume>318</volume><issue>5</issue><fpage>H1080</fpage><lpage>H1083</lpage><history><date date-type="received"><day>27</day><month>3</month><year>2020</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2020</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2020 the American Physiological Society</copyright-statement><copyright-year>2020</copyright-year><copyright-holder>American Physiological Society</copyright-holder></permissions><self-uri content-type="pdf" xlink:href="ajpheart.00215.2020.pdf"/><funding-group><award-group id="award1"><funding-source><named-content content-type="funder-name">Israeli Science Foundation</named-content></funding-source><award-id>No. 544/18</award-id></award-group></funding-group></article-meta></front><body><p><sc>to the editor</sc>: Emerging clinical reports from China, Italy, and the United States reveal that SARS-CoV-2 is associated with a prominent incidence of cardiovascular morbidities and complications (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B36" ref-type="bibr">36</xref>), including myocarditis, acute myocardial infarction, and worsening heart failure. These cardiovascular manifestations have been encountered in preceding epidemics of corona viruses, namely Severe Acute Respiratory Syndrome (SARS) and Middle-East Respiratory Syndrome (MERS), as well as during H1N1 influenza outbreaks (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B36" ref-type="bibr">36</xref>). Moreover, several preliminary reports indicate that a vast majority of patients with comorbidities are prone to SARS-CoV-2 complications (50&#x02013;86%). Congestive heart failure (CHF), chronic kidney disease (CKD), diabetes, and pulmonary diseases are the principal-identified clinical conditions predisposing to SARS-CoV-2-induced morbidities and mortality (<xref rid="B7" ref-type="bibr">7</xref>). Although pneumonia, the principal alarming feature of SARS-CoV-2 infection, could by itself evoke cardiovascular complications as a result of hypoxemia, systemic inflammation and enhanced myocardial oxygen demand, a direct cardiovascular injury, likely develops, initiated by binding of SARS-CoV-2 to angiotensin-converting enzyme 2 (ACE2), widely expressed in myocardial and vascular endothelial cells, leading to adverse cardiovascular consequences. The following short commentary outlines potential mechanisms by which elimination of ACE2 by this virus may lead to deleterious cardiovascular outcome.</p><p>ACE2 is a transcellular protein predominantly expressed in the heart, vasculature, kidney, lung, brain, intestine, and testis and is usually located at the apical side of cells attached to basal membrane (<xref ref-type="fig" rid="F0001">Fig. 1</xref>) (<xref rid="B30" ref-type="bibr">30</xref>). In the heart, ACE2 is widely expressed in all cardiac cell types, including endothelial cells, smooth muscle cells in the myocardial vasculature and in cardiac myocytes (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B9" ref-type="bibr">9</xref>). ACE2 has 400-fold affinity to angiotensin II (ANG II), as compared with the classic ACE, and it converts ANG II to angiotensin-(1&#x02013;7) [Ang-(1&#x02013;7)] (<xref rid="B31" ref-type="bibr">31</xref>). The latter short peptide exerts vasodilatory, natriuretic/diuretic, anti-inflammatory, and antifibrotic effects via Mas receptor (MasR). Noteworthy, both clinical (<xref rid="B2" ref-type="bibr">2</xref>, <xref rid="B3" ref-type="bibr">3</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B37" ref-type="bibr">37</xref>) and experimental (<xref rid="B2" ref-type="bibr">2</xref>) heart failure is characterized by upregulation of cardiac ACE2 and enhanced Ang-(1&#x02013;7) generation, which may represent a cardioprotective compensatory response aimed at reducing or preventing cardiac remodeling (<xref rid="B28" ref-type="bibr">28</xref>) (<xref ref-type="fig" rid="F0001">Fig. 1</xref>). In agreement with this notion, targeted overexpression of cardiac ACE2 by applying local injection of lenti-viral vector in Sprague-Dawley normotensive rats significantly attenuated cardiac hypertrophy and myocardial fibrosis induced by prolonged ANG II administration (<xref rid="B15" ref-type="bibr">15</xref>). Similarly, overexpression of ACE2 in cardiac tissues of spontaneously hypertensive rats decreased cardiac remodeling in as was evident by reduced left ventricular wall thickness and perivascular fibrosis (<xref rid="B6" ref-type="bibr">6</xref>), probably via reduction of collagen production (<xref rid="B11" ref-type="bibr">11</xref>). Collectively, these animal studies highlight a cardioprotective role for the ACE2&#x02013;Ang-(<xref rid="B1" ref-type="bibr">1</xref>&#x02013;<xref rid="B7" ref-type="bibr">7</xref>)&#x02013;MasR axis.</p><fig fig-type="figure" id="F0001" orientation="portrait" position="float"><label>Fig. 1.</label><caption><p>The initial step after the invasion of Severe Acute Respiratory Syndrome (SARS)-CoV-2 is binding to membranal angiotensin-converting enzyme 2 (ACE2) widely expressed in cardiac cells including endothelial cells, smooth muscle cells in the myocardial vasculature and in cardiac myocytes. ACE2 is responsible for the conversion of ANG II to Ang-(1&#x02013;7) that exerts beneficial effects on the cardiac tissue such as vasodilation, antifibrosis, and anti-inflammation via Mas receptor (MasR). The binding of SARS-CoV-2 to ACE2 is preceded by furin-mediated exposure of the viral receptor binding protein (RBP) localized to <italic>S</italic>-glycoprotein (S1 domain of the viral spike). Furin is abundant in the heart both intracellulary and in the circulation as a free enzyme, making it a key factor in the uncovering of RBP and eventually in SARS-CoV-2 transmission. In addition, furin enhances the affinity of the virus to ACE2 by not only exposing the viral binding site on S1 domain but also revealing the effusion site on the S2 domain in the viral spike. Consequently, the virus undergoes endocytosis and massive replication accompanied by profound activation by cathespsin L (CatL) and the abundant intracellular furin. The activated intracellular SARS-CoV-2 undergoes exocytosis where it binds again to ACE2 elsewhere, thus creating a vicious feed-forward devastating cycle. Importantly, heart failure is characterized by enhanced expression of myocardial ACE2, which is further upregulated by ACE-I, angiotensin receptor blockers (ARBs), and mineralocorticoid-receptor (MR) antagonists, thus sensitizing ACE2 expressing target organs to SARS-CoV-2. ADAM metallopeptidase domain 17 (ADAM 17) is responsible for shading of ACE2, a process stimulated by ANG II type 1 receptors (AT<sub>1</sub>-R) and may explain why renin-angiotensin-aldosterone system inhibitors augment ACE2 expression. ER, endoplasmic reticulum.</p></caption><graphic xlink:href="zh40052030800001"/></fig><p>Binding of the SARS viral spike glycoprotein to ACE2 triggers its internalization along with the virus (<xref rid="B13" ref-type="bibr">13</xref>). This might be of supreme importance for cardiomyocytes of patients with heart failure, characterized by intense upregulation of ACE2 (<xref rid="B9" ref-type="bibr">9</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B37" ref-type="bibr">37</xref>) (<xref ref-type="fig" rid="F0001">Fig. 1</xref>). Possibly, intracellular translocation of SARS-CoV-2 coupled with ACE2 leads to its depletion in cell membranes. It is tempting to assume that consequent ACE2 elimination might participate in many features of acute corona virus infection. Among such clinical characteristics are decompensation of preexisting CHF, respiratory distress irrespective to left-ventricular backward failure (due to impaired pulmonary capillary endothelium and endothelial barrier function), acute kidney failure (reflecting altered renal microcirculation and hypoxic injury), and diarrhea (caused by injured gut microcirculation with hypoxic damage and injured mucosal barrier.</p><p>Indeed, corona virus has already been shown to induce myocardial inflammation and dysfunction accompanied with adverse cardiac outcomes in patients with SARS, assumedly due to downregulation/elimination of the myocardial ACE2 system (<xref rid="B25" ref-type="bibr">25</xref>). Support for this concept emerges from previous experimental reports demonstrating cardiac contractility defects in rats with reduced X chromosomal-derived ACE2 expression and heart failure with pulmonary congestion in ACE2-knockout mice (ACE2-KO) (<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B34" ref-type="bibr">34</xref>). These undesired changes were prominent in males and progressed with age, coincidentally overlapping the observations that elderly and men are more susceptible to SARS-CoV-2-induced serious infection. Interestingly, the hearts of animals depleted of ACE2 exhibited similar changes that occur after coronary artery disease or bypass surgery in humans (<xref rid="B5" ref-type="bibr">5</xref>). Subsequent studies demonstrated extended infarct size, reduced contractility, altered ventricular remodeling, and increased mortality following myocardial infarction (MI) induced by ligation of the proximal LAD in mice with ACE2 deletion, as compared with their wild-type controls (<xref rid="B20" ref-type="bibr">20</xref>). Moreover, these mice showed enhanced oxidative stress and concomitant upregulation of proinflammatory cytokines, plausibly parallel to the observed hypersensitive immunological response reported in patients with SARS-CoV-2 infection.</p><p>Furthermore, preliminary alarming data from SARS-CoV-2-infected patients suggested that those treated with renin-angiotensin-aldosterone (RAAS) inhibitors such as angiotensin-converting enzyme inhibitors (ACE-I) or angiotensin-receptor blockers (ARBs) experienced severe symptoms with a higher mortality rate as compared with nonuser counterparts (<xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B26" ref-type="bibr">26</xref>). Noteworthy, cardiac ACE2 expression is markedly enhanced in response to RAAS blockade by ACEi (<xref rid="B24" ref-type="bibr">24</xref>), ARB (<xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>), and even by mineralocorticoid receptor (MR) antagonist (<xref rid="B19" ref-type="bibr">19</xref>, <xref rid="B21" ref-type="bibr">21</xref>) (<xref ref-type="fig" rid="F0001">Fig. 1</xref>). Conceivably, this is translated into increased vulnerability of patients with RAAS blockade during SARS-CoV-2 infection. Furthermore, several studies have demonstrated that binding of ANG II to its AT<sub>1</sub> receptors in target organs, including the heart, activates ADAM 17, a sheddase affecting ACE2 (<xref rid="B22" ref-type="bibr">22</xref>) (<xref ref-type="fig" rid="F0001">Fig. 1</xref>). Conclusively, blocking ANG II synthesis or its binding to AT<sub>1</sub> receptors by RAAS inhibitors likely leads to the upregulation of ACE2 and eventually hypersensitizing the heart to SARS-CoV-2 infection. Enhancement of myocardial invasion by the virus due to enhanced ACE2 likely plays an important role.</p><p>An additional player that may contribute to the vulnerability of patients with heart failure to SARS-CoV-2 is furin, also termed paired basic amino acid-cleaving enzyme (PACE). Furin is essential for permeating viral functionality as it cleaves viral envelope trimeric transmembrane glycoprotein (<italic>S</italic>) (<xref rid="B12" ref-type="bibr">12</xref>, <xref rid="B14" ref-type="bibr">14</xref>, <xref rid="B29" ref-type="bibr">29</xref>). This <italic>S</italic>-glycoprotein, vital for the entry of the virus into the cell, contains two functional domains: an ACE2-binding domain (also called receptor-binding domain (RBD) and a second domain essential for fusion of the viral and cell membranes (<xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B35" ref-type="bibr">35</xref>). Furin activity exposes the binding and fusion domains essential for the entry of the virus into the cell (<xref rid="B32" ref-type="bibr">32</xref>). Furin presents mainly intracellularly and to a lesser extent in the circulation (<xref rid="B16" ref-type="bibr">16</xref>) (<xref ref-type="fig" rid="F0001">Fig. 1</xref>), where it converts ventricular proBNP to active BNP, an important physiological process in heart failure subjects. Patients with heart failure are specifically characterized by upregulation of cardiac furin, providing an additional potential explanation for their vulnerability Covid-19 infection (<xref rid="B17" ref-type="bibr">17</xref>) (<xref ref-type="fig" rid="F0001">Fig. 1</xref>). Moreover, furin is detected in circulating T cells that are activated during infections (<xref rid="B27" ref-type="bibr">27</xref>). This may form a feed-forward loop of furin-facilitated coronavirus replication that may be responsible for hypersensitive immunological response (cytokine storm) in some patients, leading to fulminant myocarditis, devastating lung injury, and lethal multiorgan failure.</p><p>Collectively, evidently ACE2 exerts beneficial effects on cardiac function under normal conditions and particularly in the presence of heart failure. Moreover, some of the cardioprotective effects of ACE inhibitors, ARBs, and MR blockers are mediated by their positive impact on ACE2 abundance in cardiac tissues. Nevertheless, in patients infected with SARS-CoV-2, ACE2 may transform to a Trojan horse. Its binding with ACE2 neutralizes the advantageous cardiac effects of this enzyme, especially in patients with heart failure. The susceptibility of these subjects to life-threatening SARS-CoV-2 infection could be attributed to the simultaneous upregulation of both ACE2 and furin in the diseased myocardium and to the wide use of RAAS inhibitors in this population (<xref ref-type="fig" rid="F0001">Fig. 1</xref>). Therefore, temporary blockade of the viral binding site on ACE2 or furin by immunological or pharmacological means in patients infected with SARS-CoV-2 may compose new therapeutic strategies in combating this unprecedented formidable viral threat.</p><sec id="sec1"><title>GRANTS</title><p content-type="financial-disclosure">Z. Abassi acknowledges research support from the Israel Science Foundation Grant 544/18.</p></sec><sec sec-type="COI-statement" id="sec2"><title>DISCLOSURES</title><p content-type="conflict">No conflicts of interest, financial or otherwise, are declared by the authors.</p></sec><sec id="sec3"><title>AUTHOR CONTRIBUTIONS</title><p content-type="con">Z.A.A. and E.E.K. prepared figure; Z.A.A., S.A., E.E.K., and S.N.H. drafted manuscript; Z.A.A., S.A., E.E.K., and S.N.H. edited and revised manuscript; Z.A.A., S.A., E.E.K., and S.N.H. approved final version of manuscript.</p></sec></body><back><ack><title>ACKNOWLEDGMENTS</title><p>We are grateful to Safa Kinaneh for technical assistance.</p></ack><ref-list><title>REFERENCES</title><ref id="B1"><label>1.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Arentz</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Yim</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Klaff</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Lokhandwala</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Riedo</surname><given-names>FX</given-names></name>, <name name-style="western"><surname>Chong</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Lee</surname><given-names>M</given-names></name></person-group>
<article-title>Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State</article-title>. <source>JAMA</source>. <year>2020</year>
<month>3</month>
<day>19</day> [Epub ahead of print]. doi:<pub-id pub-id-type="doi">10.1001/jama.2020.4326</pub-id>. <?supplied-pmid 32191259?><pub-id pub-id-type="pmid">32191259</pub-id></mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burrell</surname><given-names>LM</given-names></name>, <name name-style="western"><surname>Risvanis</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Kubota</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Dean</surname><given-names>RG</given-names></name>, <name name-style="western"><surname>MacDonald</surname><given-names>PS</given-names></name>, <name name-style="western"><surname>Lu</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Tikellis</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Grant</surname><given-names>SL</given-names></name>, <name name-style="western"><surname>Lew</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Johnston</surname><given-names>CI</given-names></name></person-group>
<article-title>Myocardial infarction increases ACE2 expression in rat and humans</article-title>. <source>Eur Heart J</source>
<volume>26</volume>: <fpage>369</fpage>&#x02013;<lpage>375</lpage>, <year>2005</year>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehi114</pub-id>. <?supplied-pmid 15671045?><pub-id pub-id-type="pmid">15671045</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clarke</surname><given-names>NE</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>AJ</given-names></name></person-group>
<article-title>Angiotensin-converting enzyme 2: the first decade</article-title>. <source>Int J Hypertens</source>
<volume>2012</volume>: <elocation-id>307315</elocation-id>, <year>2012</year>. doi:<pub-id pub-id-type="doi">10.1155/2012/307315</pub-id>. <?supplied-pmid 22121476?><pub-id pub-id-type="pmid">22121476</pub-id></mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Crackower</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Sarao</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Oudit</surname><given-names>GY</given-names></name>, <name name-style="western"><surname>Yagil</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Kozieradzki</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Scanga</surname><given-names>SE</given-names></name>, <name name-style="western"><surname>Oliveira-dos-Santos</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>da Costa</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Pei</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Scholey</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Ferrario</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Manoukian</surname><given-names>AS</given-names></name>, <name name-style="western"><surname>Chappell</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Backx</surname><given-names>PH</given-names></name>, <name name-style="western"><surname>Yagil</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Penninger</surname><given-names>JM</given-names></name></person-group>
<article-title>Angiotensin-converting enzyme 2 is an essential regulator of heart function</article-title>. <source>Nature</source>
<volume>417</volume>: <fpage>822</fpage>&#x02013;<lpage>828</lpage>, <year>2002</year>. doi:<pub-id pub-id-type="doi">10.1038/nature00786</pub-id>. <?supplied-pmid 12075344?><pub-id pub-id-type="pmid">12075344</pub-id></mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danilczyk</surname><given-names>U</given-names></name>, <name name-style="western"><surname>Penninger</surname><given-names>JM</given-names></name></person-group>
<article-title>Angiotensin-converting enzyme II in the heart and the kidney</article-title>. <source>Circ Res</source>
<volume>98</volume>: <fpage>463</fpage>&#x02013;<lpage>471</lpage>, <year>2006</year>. doi:<pub-id pub-id-type="doi">10.1161/01.RES.0000205761.22353.5f</pub-id>. <?supplied-pmid 16514079?><pub-id pub-id-type="pmid">16514079</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>D&#x000ed;ez-Freire</surname><given-names>C</given-names></name>, <name name-style="western"><surname>V&#x000e1;zquez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Correa de Adjounian</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Ferrari</surname><given-names>MF</given-names></name>, <name name-style="western"><surname>Yuan</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Silver</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Torres</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Raizada</surname><given-names>MK</given-names></name></person-group>
<article-title>ACE2 gene transfer attenuates hypertension-linked pathophysiological changes in the SHR</article-title>. <source>Physiol Genomics</source>
<volume>27</volume>: <fpage>12</fpage>&#x02013;<lpage>19</lpage>, <year>2006</year>. doi:<pub-id pub-id-type="doi">10.1152/physiolgenomics.00312.2005</pub-id>. <?supplied-pmid 16788004?><pub-id pub-id-type="pmid">16788004</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fang</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Karakiulakis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Roth</surname><given-names>M</given-names></name></person-group>
<article-title>Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?</article-title>
<source>Lancet Respir Med</source>
<volume>pii</volume>: <elocation-id>S2213-2600(20)30116-8</elocation-id>, <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1016/S2213-2600(20)30116-8</pub-id>. <?supplied-pmid 32171062?><pub-id pub-id-type="pmid">32171062</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ferrario</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Jessup</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Chappell</surname><given-names>MC</given-names></name>, <name name-style="western"><surname>Averill</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Brosnihan</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Tallant</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Diz</surname><given-names>DI</given-names></name>, <name name-style="western"><surname>Gallagher</surname><given-names>PE</given-names></name></person-group>
<article-title>Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2</article-title>. <source>Circulation</source>
<volume>111</volume>: <fpage>2605</fpage>&#x02013;<lpage>2610</lpage>, <year>2005</year>. doi:<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.104.510461</pub-id>. <?supplied-pmid 15897343?><pub-id pub-id-type="pmid">15897343</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gallagher</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Ferrario</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Tallant</surname><given-names>EA</given-names></name></person-group>
<article-title>Regulation of ACE2 in cardiac myocytes and fibroblasts</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<volume>295</volume>: <fpage>H2373</fpage>&#x02013;<lpage>H2379</lpage>, <year>2008</year>. doi:<pub-id pub-id-type="doi">10.1152/ajpheart.00426.2008</pub-id>. <?supplied-pmid 18849338?><pub-id pub-id-type="pmid">18849338</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goulter</surname><given-names>AB</given-names></name>, <name name-style="western"><surname>Goddard</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Allen</surname><given-names>JC</given-names></name>, <name name-style="western"><surname>Clark</surname><given-names>KL</given-names></name></person-group>
<article-title>ACE2 gene expression is up-regulated in the human failing heart</article-title>. <source>BMC Med</source>
<volume>2</volume>: <fpage>19</fpage>, <year>2004</year>. doi:<pub-id pub-id-type="doi">10.1186/1741-7015-2-19</pub-id>. <?supplied-pmid 15151696?><pub-id pub-id-type="pmid">15151696</pub-id></mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Grobe</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Der Sarkissian</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Meszaros</surname><given-names>JG</given-names></name>, <name name-style="western"><surname>Raizada</surname><given-names>MK</given-names></name>, <name name-style="western"><surname>Katovich</surname><given-names>MJ</given-names></name></person-group>
<article-title>ACE2 overexpression inhibits hypoxia-induced collagen production by cardiac fibroblasts</article-title>. <source>Clin Sci (Lond)</source>
<volume>113</volume>: <fpage>357</fpage>&#x02013;<lpage>364</lpage>, <year>2007</year>. doi:<pub-id pub-id-type="doi">10.1042/CS20070160</pub-id>. <?supplied-pmid 17600530?><pub-id pub-id-type="pmid">17600530</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hallenberger</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Bosch</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Angliker</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Shaw</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Klenk</surname><given-names>HD</given-names></name>, <name name-style="western"><surname>Garten</surname><given-names>W</given-names></name></person-group>
<article-title>Inhibition of furin-mediated cleavage activation of HIV-1 glycoprotein gp160</article-title>. <source>Nature</source>
<volume>360</volume>: <fpage>358</fpage>&#x02013;<lpage>361</lpage>, <year>1992</year>. doi:<pub-id pub-id-type="doi">10.1038/360358a0</pub-id>. <?supplied-pmid 1360148?><pub-id pub-id-type="pmid">1360148</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hamming</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Cooper</surname><given-names>ME</given-names></name>, <name name-style="western"><surname>Haagmans</surname><given-names>BL</given-names></name>, <name name-style="western"><surname>Hooper</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Korstanje</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Osterhaus</surname><given-names>AD</given-names></name>, <name name-style="western"><surname>Timens</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Navis</surname><given-names>G</given-names></name>, <name name-style="western"><surname>van Goor</surname><given-names>H</given-names></name></person-group>
<article-title>The emerging role of ACE2 in physiology and disease</article-title>. <source>J Pathol</source>
<volume>212</volume>: <fpage>1</fpage>&#x02013;<lpage>11</lpage>, <year>2007</year>. doi:<pub-id pub-id-type="doi">10.1002/path.2162</pub-id>. <?supplied-pmid 17464936?><pub-id pub-id-type="pmid">17464936</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hosaka</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nagahama</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kim</surname><given-names>WS</given-names></name>, <name name-style="western"><surname>Watanabe</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Hatsuzawa</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ikemizu</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Murakami</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Nakayama</surname><given-names>K</given-names></name></person-group>
<article-title>Arg-X-Lys/Arg-Arg motif as a signal for precursor cleavage catalyzed by furin within the constitutive secretory pathway</article-title>. <source>J Biol Chem</source>
<volume>266</volume>: <fpage>12127</fpage>&#x02013;<lpage>12130</lpage>, <year>1991</year>. <?supplied-pmid 1905715?><pub-id pub-id-type="pmid">1905715</pub-id></mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Huentelman</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Grobe</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Vazquez</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Stewart</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Mecca</surname><given-names>AP</given-names></name>, <name name-style="western"><surname>Katovich</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Ferrario</surname><given-names>CM</given-names></name>, <name name-style="western"><surname>Raizada</surname><given-names>MK</given-names></name></person-group>
<article-title>Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats</article-title>. <source>Exp Physiol</source>
<volume>90</volume>: <fpage>783</fpage>&#x02013;<lpage>790</lpage>, <year>2005</year>. doi:<pub-id pub-id-type="doi">10.1113/expphysiol.2005.031096</pub-id>. <?supplied-pmid 16049057?><pub-id pub-id-type="pmid">16049057</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichiki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Burnett</surname><given-names>JC</given-names><suffix>Jr</suffix></name></person-group>
<article-title>Post-transcriptional modification of pro-BNP in heart failure: is glycosylation and circulating furin key for cardiovascular homeostasis?</article-title>
<source>Eur Heart J</source>
<volume>35</volume>: <fpage>3001</fpage>&#x02013;<lpage>3003</lpage>, <year>2014</year>. doi:<pub-id pub-id-type="doi">10.1093/eurheartj/ehu381</pub-id>. <?supplied-pmid 25246481?><pub-id pub-id-type="pmid">25246481</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ichiki</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Huntley</surname><given-names>BK</given-names></name>, <name name-style="western"><surname>Burnett</surname><given-names>JC</given-names><suffix>Jr</suffix></name></person-group>
<article-title>BNP molecular forms and processing by the cardiac serine protease corin</article-title>. <source>Adv Clin Chem</source>
<volume>61</volume>: <fpage>1</fpage>&#x02013;<lpage>31</lpage>, <year>2013</year>. doi:<pub-id pub-id-type="doi">10.1016/B978-0-12-407680-8.00001-4</pub-id>. <?supplied-pmid 24015598?><pub-id pub-id-type="pmid">24015598</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ishiyama</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Gallagher</surname><given-names>PE</given-names></name>, <name name-style="western"><surname>Averill</surname><given-names>DB</given-names></name>, <name name-style="western"><surname>Tallant</surname><given-names>EA</given-names></name>, <name name-style="western"><surname>Brosnihan</surname><given-names>KB</given-names></name>, <name name-style="western"><surname>Ferrario</surname><given-names>CM</given-names></name></person-group>
<article-title>Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors</article-title>. <source>Hypertension</source>
<volume>43</volume>: <fpage>970</fpage>&#x02013;<lpage>976</lpage>, <year>2004</year>. doi:<pub-id pub-id-type="doi">10.1161/01.HYP.0000124667.34652.1a</pub-id>. <?supplied-pmid 15007027?><pub-id pub-id-type="pmid">15007027</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karram</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Abbasi</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Keidar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Golomb</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hochberg</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Winaver</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Hoffman</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Abassi</surname><given-names>Z</given-names></name></person-group>
<article-title>Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure</article-title>. <source>Am J Physiol Heart Circ Physiol</source>
<volume>289</volume>: <fpage>H1351</fpage>&#x02013;<lpage>H1358</lpage>, <year>2005</year>. doi:<pub-id pub-id-type="doi">10.1152/ajpheart.01186.2004</pub-id>. <?supplied-pmid 15894569?><pub-id pub-id-type="pmid">15894569</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kassiri</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Zhong</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Guo</surname><given-names>D</given-names></name>, <name name-style="western"><surname>Basu</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>X</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Scholey</surname><given-names>JW</given-names></name>, <name name-style="western"><surname>Penninger</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Oudit</surname><given-names>GY</given-names></name></person-group>
<article-title>Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction</article-title>. <source>Circ Heart Fail</source>
<volume>2</volume>: <fpage>446</fpage>&#x02013;<lpage>455</lpage>, <year>2009</year>. doi:<pub-id pub-id-type="doi">10.1161/CIRCHEARTFAILURE.108.840124</pub-id>. <?supplied-pmid 19808375?><pub-id pub-id-type="pmid">19808375</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Keidar</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Gamliel-Lazarovich</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Kaplan</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Pavlotzky</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hamoud</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Hayek</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Karry</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Abassi</surname><given-names>Z</given-names></name></person-group>
<article-title>Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients</article-title>. <source>Circ Res</source>
<volume>97</volume>: <fpage>946</fpage>&#x02013;<lpage>953</lpage>, <year>2005</year>. doi:<pub-id pub-id-type="doi">10.1161/01.RES.0000187500.24964.7A</pub-id>. <?supplied-pmid 16179584?><pub-id pub-id-type="pmid">16179584</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lambert</surname><given-names>DW</given-names></name>, <name name-style="western"><surname>Yarski</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Warner</surname><given-names>FJ</given-names></name>, <name name-style="western"><surname>Thornhill</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Parkin</surname><given-names>ET</given-names></name>, <name name-style="western"><surname>Smith</surname><given-names>AI</given-names></name>, <name name-style="western"><surname>Hooper</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>AJ</given-names></name></person-group>
<article-title>Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2)</article-title>. <source>J Biol Chem</source>
<volume>280</volume>: <fpage>30113</fpage>&#x02013;<lpage>30119</lpage>, <year>2005</year>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M505111200</pub-id>. <?supplied-pmid 15983030?><pub-id pub-id-type="pmid">15983030</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Moore</surname><given-names>MJ</given-names></name>, <name name-style="western"><surname>Vasilieva</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Sui</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Wong</surname><given-names>SK</given-names></name>, <name name-style="western"><surname>Berne</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Somasundaran</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Sullivan</surname><given-names>JL</given-names></name>, <name name-style="western"><surname>Luzuriaga</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Greenough</surname><given-names>TC</given-names></name>, <name name-style="western"><surname>Choe</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Farzan</surname><given-names>M</given-names></name></person-group>
<article-title>Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus</article-title>. <source>Nature</source>
<volume>426</volume>: <fpage>450</fpage>&#x02013;<lpage>454</lpage>, <year>2003</year>. doi:<pub-id pub-id-type="doi">10.1038/nature02145</pub-id>. <?supplied-pmid 14647384?><pub-id pub-id-type="pmid">14647384</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ocaranza</surname><given-names>MP</given-names></name>, <name name-style="western"><surname>Godoy</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Jalil</surname><given-names>JE</given-names></name>, <name name-style="western"><surname>Varas</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Collantes</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Pinto</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Roman</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Ramirez</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Copaja</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Diaz-Araya</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Castro</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Lavandero</surname><given-names>S</given-names></name></person-group>
<article-title>Enalapril attenuates downregulation of Angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat</article-title>. <source>Hypertension</source>
<volume>48</volume>: <fpage>572</fpage>&#x02013;<lpage>578</lpage>, <year>2006</year>. doi:<pub-id pub-id-type="doi">10.1161/01.HYP.0000237862.94083.45</pub-id>. <?supplied-pmid 16908757?><pub-id pub-id-type="pmid">16908757</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Oudit</surname><given-names>GY</given-names></name>, <name name-style="western"><surname>Kassiri</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Jiang</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Liu</surname><given-names>PP</given-names></name>, <name name-style="western"><surname>Poutanen</surname><given-names>SM</given-names></name>, <name name-style="western"><surname>Penninger</surname><given-names>JM</given-names></name>, <name name-style="western"><surname>Butany</surname><given-names>J</given-names></name></person-group>
<article-title>SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS</article-title>. <source>Eur J Clin Invest</source>
<volume>39</volume>: <fpage>618</fpage>&#x02013;<lpage>625</lpage>, <year>2009</year>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2362.2009.02153.x</pub-id>. <?supplied-pmid 19453650?><pub-id pub-id-type="pmid">19453650</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perico</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Benigni</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Remuzzi</surname><given-names>G</given-names></name></person-group>
<article-title>Should COVID-19 Concern Nephrologists? Why and to What Extent? The Emerging Impasse of Angiotensin Blockade</article-title>. <source>Nephron</source>
<volume>23</volume>: <fpage>1</fpage>&#x02013;<lpage>9</lpage>, <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1159/000507305</pub-id>. <?supplied-pmid 32203970?><pub-id pub-id-type="pmid">32203970</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pesu</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Watford</surname><given-names>WT</given-names></name>, <name name-style="western"><surname>Wei</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Xu</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Fuss</surname><given-names>I</given-names></name>, <name name-style="western"><surname>Strober</surname><given-names>W</given-names></name>, <name name-style="western"><surname>Andersson</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Shevach</surname><given-names>EM</given-names></name>, <name name-style="western"><surname>Quezado</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Bouladoux</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Roebroek</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Belkaid</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Creemers</surname><given-names>J</given-names></name>, <name name-style="western"><surname>O&#x02019;Shea</surname><given-names>JJ</given-names></name></person-group>
<article-title>T-cell-expressed proprotein convertase furin is essential for maintenance of peripheral immune tolerance</article-title>. <source>Nature</source>
<volume>455</volume>: <fpage>246</fpage>&#x02013;<lpage>250</lpage>, <year>2008</year>. doi:<pub-id pub-id-type="doi">10.1038/nature07210</pub-id>. <?supplied-pmid 18701887?><pub-id pub-id-type="pmid">18701887</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Santos</surname><given-names>RA</given-names></name>, <name name-style="western"><surname>Ferreira</surname><given-names>AJ</given-names></name>, <name name-style="western"><surname>Sim&#x000f5;es E Silva</surname><given-names>AC</given-names></name></person-group>
<article-title>Recent advances in the angiotensin-converting enzyme 2-angiotensin(1-7)-Mas axis</article-title>. <source>Exp Physiol</source>
<volume>93</volume>: <fpage>519</fpage>&#x02013;<lpage>527</lpage>, <year>2008</year>. doi:<pub-id pub-id-type="doi">10.1113/expphysiol.2008.042002</pub-id>. <?supplied-pmid 18310257?><pub-id pub-id-type="pmid">18310257</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>G</given-names></name></person-group>
<article-title>Furin at the cutting edge: from protein traffic to embryogenesis and disease</article-title>. <source>Nat Rev Mol Cell Biol</source>
<volume>3</volume>: <fpage>753</fpage>&#x02013;<lpage>766</lpage>, <year>2002</year>. doi:<pub-id pub-id-type="doi">10.1038/nrm934</pub-id>. <?supplied-pmid 12360192?><pub-id pub-id-type="pmid">12360192</pub-id></mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tipnis</surname><given-names>SR</given-names></name>, <name name-style="western"><surname>Hooper</surname><given-names>NM</given-names></name>, <name name-style="western"><surname>Hyde</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Karran</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Christie</surname><given-names>G</given-names></name>, <name name-style="western"><surname>Turner</surname><given-names>AJ</given-names></name></person-group>
<article-title>A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase</article-title>. <source>J Biol Chem</source>
<volume>275</volume>: <fpage>33238</fpage>&#x02013;<lpage>33243</lpage>, <year>2000</year>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M002615200</pub-id>. <?supplied-pmid 10924499?><pub-id pub-id-type="pmid">10924499</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vickers</surname><given-names>C</given-names></name>, <name name-style="western"><surname>Hales</surname><given-names>P</given-names></name>, <name name-style="western"><surname>Kaushik</surname><given-names>V</given-names></name>, <name name-style="western"><surname>Dick</surname><given-names>L</given-names></name>, <name name-style="western"><surname>Gavin</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Tang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Godbout</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Parsons</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Baronas</surname><given-names>E</given-names></name>, <name name-style="western"><surname>Hsieh</surname><given-names>F</given-names></name>, <name name-style="western"><surname>Acton</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Patane</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Nichols</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Tummino</surname><given-names>P</given-names></name></person-group>
<article-title>Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase</article-title>. <source>J Biol Chem</source>
<volume>277</volume>: <fpage>14838</fpage>&#x02013;<lpage>14843</lpage>, <year>2002</year>. doi:<pub-id pub-id-type="doi">10.1074/jbc.M200581200</pub-id>. <?supplied-pmid 11815627?><pub-id pub-id-type="pmid">11815627</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walls</surname><given-names>AC</given-names></name>, <name name-style="western"><surname>Park</surname><given-names>YJ</given-names></name>, <name name-style="western"><surname>Tortorici</surname><given-names>MA</given-names></name>, <name name-style="western"><surname>Wall</surname><given-names>A</given-names></name>, <name name-style="western"><surname>McGuire</surname><given-names>AT</given-names></name>, <name name-style="western"><surname>Veesler</surname><given-names>D</given-names></name></person-group>
<article-title>Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>. <source>Cell</source>
<volume>pii</volume>: <elocation-id>S0092-8674(20)30262-2</elocation-id>, <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1016/j.cell.2020.02.058</pub-id>. <?supplied-pmid 32155444?><pub-id pub-id-type="pmid">32155444</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wan</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shang</surname><given-names>J</given-names></name>, <name name-style="western"><surname>Graham</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Baric</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Li</surname><given-names>F</given-names></name></person-group>
<article-title>Receptor recognition by the novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus</article-title>. <source>J Virol</source>
<volume>94</volume>: <elocation-id>e00127-20</elocation-id>, <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1128/JVI.00127-20</pub-id>. <?supplied-pmid 31996437?><pub-id pub-id-type="pmid">31996437</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yamamoto</surname><given-names>K</given-names></name>, <name name-style="western"><surname>Ohishi</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Katsuya</surname><given-names>T</given-names></name>, <name name-style="western"><surname>Ito</surname><given-names>N</given-names></name>, <name name-style="western"><surname>Ikushima</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Kaibe</surname><given-names>M</given-names></name>, <name name-style="western"><surname>Tatara</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Shiota</surname><given-names>A</given-names></name>, <name name-style="western"><surname>Sugano</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Takeda</surname><given-names>S</given-names></name>, <name name-style="western"><surname>Rakugi</surname><given-names>H</given-names></name>, <name name-style="western"><surname>Ogihara</surname><given-names>T</given-names></name></person-group>
<article-title>Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II</article-title>. <source>Hypertension</source>
<volume>47</volume>: <fpage>718</fpage>&#x02013;<lpage>726</lpage>, <year>2006</year>. doi:<pub-id pub-id-type="doi">10.1161/01.HYP.0000205833.89478.5b</pub-id>. <?supplied-pmid 16505206?><pub-id pub-id-type="pmid">16505206</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="other"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhao</surname><given-names>Z</given-names></name>, <name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>Y</given-names></name>, <name name-style="western"><surname>Zuo</surname><given-names>W.</given-names></name></person-group>
<article-title>Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov</article-title>. [Preprint]. <source>bioRxiv</source>. <year>2020</year>. doi:<pub-id pub-id-type="doi">10.1101/2020.01.26.919985</pub-id>.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>YY</given-names></name>, <name name-style="western"><surname>Ma</surname><given-names>YT</given-names></name>, <name name-style="western"><surname>Zhang</surname><given-names>JY</given-names></name>, <name name-style="western"><surname>Xie</surname><given-names>X</given-names></name></person-group>
<article-title>COVID-19 and the cardiovascular system</article-title>. <source>Nat Rev Cardiol</source>, <year>2020</year>
<month>3</month>
<day>5</day> [Epub ahead of print]. doi:<pub-id pub-id-type="doi">10.1038/s41569-020-0360-5</pub-id>. <?supplied-pmid 32139904?><pub-id pub-id-type="pmid">32139904</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zisman</surname><given-names>LS</given-names></name>, <name name-style="western"><surname>Keller</surname><given-names>RS</given-names></name>, <name name-style="western"><surname>Weaver</surname><given-names>B</given-names></name>, <name name-style="western"><surname>Lin</surname><given-names>Q</given-names></name>, <name name-style="western"><surname>Speth</surname><given-names>R</given-names></name>, <name name-style="western"><surname>Bristow</surname><given-names>MR</given-names></name>, <name name-style="western"><surname>Canver</surname><given-names>CC</given-names></name></person-group>
<article-title>Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2</article-title>. <source>Circulation</source>
<volume>108</volume>: <fpage>1707</fpage>&#x02013;<lpage>1712</lpage>, <year>2003</year>. doi:<pub-id pub-id-type="doi">10.1161/01.CIR.0000094734.67990.99</pub-id>. <?supplied-pmid 14504186?><pub-id pub-id-type="pmid">14504186</pub-id></mixed-citation></ref></ref-list></back></article>